BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia

OncoImmunology

Volumn 5, Issue 10, 2016, Pages

  Benyamine, Audrey ^a   Le Roy, Aude ^a   Mamessier, Emilie ^a   Gertner Dardenne, Julie ^a   Castanier, Céline ^a   Orlanducci, Florence ^a   Pouyet, Laurent ^a   Goubard, Armelle ^a   Collette, Yves ^a   Vey, Norbert ^a,b   Scotet, Emmanuel ^c   Castellano, Remy ^a   Olive, Daniel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c INSERM   (France)

Author keywords

Acute myeloid leukemia; aminobisphosphonate; BTN3A; immunotherapy; monoclonal antibody; T cells

Indexed keywords

BUTYROPHILIN3A ANTIBODY; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CHROMIUM RELEASE ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING; XENOTRANSPLANTATION;

EID: 84991030621     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1146843     Document Type: Article

References (33)

1. A.Butturini, M.M.Bortin, R.P.Gale. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2(3):233–42; PMID:3332173
2. V.Kunzmann, E.Bauer, J.Feurle, F.Weissinger, H.P.Tony, M.Wilhelm. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96(2):384–92; PMID:10887096; http://dx.doi.org.gate2.inist.fr/
3. B.Castella, C.Vitale, M.Coscia, M.Massaia. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies:from bench to bedside. Cell Mol Life Sci CMLS 2011; 68(14):2419–32; PMID:21584812; http://dx.doi.org/10.1007/s00018-011-0704-8
4. D.Kabelitz, D.Wesch, E.Pitters, M.Zöller. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 2004; 173(11):6767–76; PMID:15557170; http://dx.doi.org/10.4049/jimmunol.173.11.6767
5. H.Norell, A.Moretta, B.Silva-Santos, L.Moretta. At the Bench:Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias. J Leukoc Biol 2013; 94(6):1123–39; PMID:24108703; http://dx.doi.org/10.1189/jlb.0613312
6. F.Locatelli, P.Merli, S.Rutella. At the Bedside:Innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol 2013; 94(6):1141–57; PMID:24096380; http://dx.doi.org/10.1189/jlb.0613343
7. K.T.Godder, P.J.Henslee-Downey, J.Mehta, B.S.Park, K.Y.Chiang, S.Abhyankar, L.S.Lamb. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39(12):751–7; PMID:17450185; http://dx.doi.org/10.1038/sj.bmt.1705650
8. P.F.Meeh, M.King, R.L.O'Brien, S.Muga, P.Buckhalts, R.Neuberg, L.S.Lamb, Jr. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother 2006; 55(9):1072–80; PMID:16328383; http://dx.doi.org/10.1007/s00262-005-0094-6
9. H.J.Gober, M.Kistowska, L.Angman, P.Jenö, L.Mori, G.De Libero. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197(2):163–8; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500
10. J.Li, M.J.Herold, B.Kimmel, I.Müller, B.Rincon-Orozco, V.Kunzmann, T.Herrmann. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells. J Immunol 2009; 182(12):8118–24; PMID:19494338; http://dx.doi.org/10.4049/jimmunol.0900101
11. I.Benzaïd, H.Mönkkönen, V.Stresing, E.Bonnelye, J.Green, J.Mönkkönen, J.L.Touraine, P.Clézardin. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011; 71(13):4562–72; PMID:21646473; http://dx.doi.org/10.1158/0008-5472.CAN-10-3862
12. J.Gertner-Dardenne, R.Castellano, E.Mamessier, S.Garbit, E.Kochbati, A.Etienne, A.Charbonnier, Y.Collette, N.Vey, D.Olive. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 2012; 188(9):4701–8; PMID:22467661; http://dx.doi.org/10.4049/jimmunol.1103710
13. V.Kunzmann, M.Smetak, B.Kimmel, K.Weigang-Koehler, M.Goebeler, J.Birkmann, J.Becker, I.G.Schmidt-Wolf, H.Einsele, M.Wilhelm. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy:results from a prospective phase I/II trial. J Immunother 2012; 35(2):205–13; PMID:22306909; http://dx.doi.org/10.1097/CJI.0b013e318245bb1e
14. M.Coscia, C.Vitale, S.Peola, M.Foglietta, M.Rigoni, V.Griggio, B.Castella, D.Angelini, S.Chiaretti, C.Riganti et al. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood 2012; 120(16):3271–9; PMID:22932792; http://dx.doi.org/10.1182/blood-2012-03-417519
15. M.Wilhelm, M.Smetak, K.Schaefer-Eckart, B.Kimmel, J.Birkmann, H.Einsele, V.Kunzmann. Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells. J Transl Med 2014; 12:45; PMID:24528541; http://dx.doi.org/10.1186/1479-5876-12-45
16. S.Gundermann, E.Klinker, B.Kimmel, U.Flierl, M.Wilhelm, H.Einsele, V.Kunzmann. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells. J Immunother 2014; 37(6):321–30; PMID:24911793; http://dx.doi.org/10.1097/CJI.0000000000000043
17. E.Compte, P.Pontarotti, Y.Collette, M.Lopez, D.Olive. Frontline:Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J Immunol 2004; 34(8):2089–99; PMID:15259006; http://dx.doi.org/10.1002/eji.200425227
18. C.Le Page, A.Marineau, P.K.Bonza, K.Rahimi, L.Cyr, I.Labouba, J.Madore, N.Delvoye, A.M.Mes-Masson, D.M.Provencher et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PloS One 2012; 7(6):e38541; PMID:22685580; http://dx.doi.org/10.1371/journal.pone.0038541
19. D.A.Rhodes, H.C.Chen, A.J.Price, A.H.Keeble, M.S.Davey, L.C.James, M.Eberl, J.Trowsdale. Activation of Human γδ T Cells by Cytosolic Interactions of BTN3A1 with Soluble Phosphoantigens and the Cytoskeletal Adaptor Periplakin. J Immunol 2015; 194(5):2390–8; PMID:25637025; http://dx.doi.org/10.4049/jimmunol.1401064
20. C.Harly, Y.Guillaume, S.Nedellec, C.M.Peigné, H.Mönkkönen, J.Mönkkönen, J.Li, J.Kuball, E.J.Adams, S.Netzer et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 2012; 120(11):2269–79; PMID:22767497; http://dx.doi.org/10.1182/blood-2012-05-430470
21. H.Wang, O.Henry, M.D.Distefano, Y.C.Wang, J.Räikkönen, J.Mönkkönen, Y.Tanaka, C.T.Morita. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol 2013; 191(3):1029–42; PMID:23833237; http://dx.doi.org/10.4049/jimmunol.1300658
22. A.Sandstrom, C.M.Peigné, A.Léger, J.E.Crooks, F.Konczak, M.C.Gesnel, R.Breathnach, M.Bonneville, E.Scotet, E.J.Adams. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014; 40(4):490–500; PMID:24703779; http://dx.doi.org/10.1016/j.immuni.2014.03.003
23. H.Wang, C.T.Morita. Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells. J Immunol 2015; 195(10):4583–94; PMID:26475929; http://dx.doi.org/10.4049/jimmunol.1500314
24. A.Palakodeti, A.Sandstrom, L.Sundaresan, C.Harly, S.Nedellec, D.Olive, E.Scotet, M.Bonneville, E.J.Adams. The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem 2012; 287(39):32780–90; PMID:22846996; http://dx.doi.org/10.1074/jbc.M112.384354
25. A.Bessard, V.Sole, G.Bouchaud, A.Quemener, Y.Jacques. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8(9):2736–45; PMID:19723883; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275
26. E.Mortier, A.Quéméner, P.Vusio, I.Lorenzen, Y.Boublik, J.Grötzinger, A.Plet, Y.Jacques. Soluble interleukin-15 receptor α (IL-15R α)-sushi as a selective and potent agonist of IL-15 action through IL-15R β/gamma. Hyperagonist IL-15 x IL-15R α fusion proteins. J Biol Chem 2006; 281(3):1612–9; PMID:16284400; http://dx.doi.org/10.1074/jbc.M508624200
27. P.V.Sanchez, R.L.Perry, J.E.Sarry, A.E.Perl, K.Murphy, C.R.Swider, A.Bagg, J.K.Choi, J.A.Biegel, G.Danet-Desnoyers et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009; 23(11):2109–17; PMID:19626050; http://dx.doi.org/10.1038/leu.2009.143
28. M.Wilhelm, V.Kunzmann, S.Eckstein, P.Reimer, F.Weissinger, T.Ruediger, H.P.Tony. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102(1):200–6; PMID:12623838; http://dx.doi.org/10.1182/blood-2002-12-3665
29. A.S.M.Idrees, T.Sugie, C.Inoue, K.Murata-Hirai, H.Okamura, C.T.Morita, N.Minato, M.Toi, Y.Tanaka. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Sci 2013; 104(5):536–42; PMID:23387443; http://dx.doi.org/10.1111/cas.12124
30. F.Riaño, M.M.Karunakaran, L.Starick, J.Li, C.J.Scholz, V.Kunzmann, D.Olive, S.Amslinger, T.Herrmann. Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6. Eur J Immunol 2014; 44(9):2571–6; http://dx.doi.org/10.1002/eji.201444712
31. N.Messal, E.Mamessier, A.Sylvain, J.Celis-Gutierrez, M.L.Thibult, B.Chetaille, G.Firaguay, S.Pastor, Y.Guillaume, Q.Wang et al. Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. Eur J Immunol 2011; 41(12):3443–54; PMID:21918970; http://dx.doi.org/10.1002/eji.201141404
32. J.Gertner, A.Wiedemann, M.Poupot, J.-J.Fournié. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett 2007; 110(1):42–53; PMID:17451812; http://dx.doi.org/10.1016/j.imlet.2007.03.002
33. J.Gertner-Dardenne, M.Poupot, B.Gray, J.J.Fournié. Lipophilic fluorochrome trackers of membrane transfers between immune cells. Immunol Invest 2007; 36(5–6):665–85; PMID:18161524; http://dx.doi.org/10.1080/08820130701674646